VaxCell-Bio applies for approval of anti-cancer drug for dogs

The request for the candidate treatment Vaxleukin-15 will first be for mammary tumors and later for lymphoma

Getty Images
Getty Images
Ye-Na Kim 1
2023-10-24 12:36:19 yena@hankyung.com
Bio & Pharma

South Korea’s VaxCell Biotherapeutics Co. (VaxCell-Bio) on Tuesday announced its application for approval for Vaxleukin-15, an anti-cancer drug candidate for pet dogs, with the Animal and Plant Quarantine Agency.

In preclinical trials on normal dogs, the company confirmed that the candidate drug activated and proliferated natural killer (NK) and T cells that remove cancerous cells. When measuring the tumor biomarkers TK1 and VEGF, the concentration of such biomarkers tended to decline after Vaxleukin-15 was administered, it added, with effectiveness and nearly no side effects seen.

VaxCell-Bio applies for approval of anti-cancer drug for dogs

Clinical trials were conducted on 120 dogs -- 60 for mammary tumors and 60 for lymphoma – at 29 veterinary institutions in the Seoul metropolitan area and 13 in Gwangju and South Jeolla Province. Application for product approval followed the trials for the tumors, which account for a high rate of cancer incidence in dogs.

VaxCell-Bio will apply for expanded approval as soon as its trials for the candidate drug’s effect on lymphoma are done.

With anti-cancer treatments for pets sold worldwide developed for human use, the company said Vaxleukin-15 is the world’s first of its kind specifically for dogs based on the canine genome, not that of a human. With practically no side effects, the candidate drug is highly effective when administered with standard treatment for each type of cancer.

At the end of this month, VaxCell-Bio will submit an abstract on preclinical data on Vaxleukin-15 to the Korean Society of Veterinary Science and at year’s end, it will make an official announcement about it at the organization’s international conference.

For entering the medical market for companion animals, VaxCell-Bio is opening a pet healthcare headquarters and building and inspecting a mass production plant for Vaxleukin-15. It plans to sell the latter through veterinary hospitals nationwide after obtaining approval next year.

Write to Ye-Na Kim at yena@hankyung.com

VaxCell Bio's treatment shows promise for advanced liver cancer

VaxCell Bio's treatment shows promise for advanced liver cancer

South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the growth of cancer cells in Phase 2a clinical trials.The tests used a combination therapy of hepatic arterial infusion chemotherapy (HAIC), which is

Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, has received "therapeutic use approval" for patients with advanced liver cancer. The approval was granted by the Korean Ministry of Food and D

Vaxcell-Bio, Cellid sign MOU to build cancer immunotherapy platform

Vaxcell-Bio, Cellid sign MOU to build cancer immunotherapy platform

Vaxcell-Bio Therapeutics, a South Korean company specializing in anti-cancer immunotherapy, announced on Wednesday its partnership with Cellid Co. to develop an advanced cancer immunotherapy platform.Vaxcell-Bio is dedicated to researching and developing various types of cancer treatments usin

(* comment hide *}